Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, ##STR00001##
as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, ##STR00001##
as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

The disclosure provides compounds of formula II with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.

##STR00001##

The disclosure provides compounds of formula II with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.

##STR00001##

The present disclosure provides intermediates used for preparing Brivaracetam, a preparation method and a use thereof, including an intermediate compound A and an intermediate compound B and a preparation method thereof, as well as a synthetic route for using the intermediate compound B to prepare Brivaracetam. The present technical solution can obtain high-quality and high-optical purity Brivaracetam and intermediates thereof, the proportion of Brivaracetam among the four optical isomers being greater than 99.5%. In addition, neither silica gel column for separation and purification nor expensive chiral high performance liquid chromatography for resolution is required, thereby avoiding cumbersome separation and purification steps, also avoiding waste of raw materials, reducing the production cost and making it more suitable for industrial production.

The present disclosure provides intermediates used for preparing Brivaracetam, a preparation method and a use thereof, including an intermediate compound A and an intermediate compound B and a preparation method thereof, as well as a synthetic route for using the intermediate compound B to prepare Brivaracetam. The present technical solution can obtain high-quality and high-optical purity Brivaracetam and intermediates thereof, the proportion of Brivaracetam among the four optical isomers being greater than 99.5%. In addition, neither silica gel column for separation and purification nor expensive chiral high performance liquid chromatography for resolution is required, thereby avoiding cumbersome separation and purification steps, also avoiding waste of raw materials, reducing the production cost and making it more suitable for industrial production.

The invention relates to new modifications of abscisic acid, to liquid compositions of abscisic acid and to their use in agrochemical applications. The modifications and compositions of the invention contain abscisic acid in the form of a solvate with at least one N-alkyl pyrrolidone, wherein the N-alkyl group has 3 to 6 carbon atoms. These solvates enable formulations with high concentrations of abscisic acid.

The invention relates to new modifications of abscisic acid, to liquid compositions of abscisic acid and to their use in agrochemical applications. The modifications and compositions of the invention contain abscisic acid in the form of a solvate with at least one N-alkyl pyrrolidone, wherein the N-alkyl group has 3 to 6 carbon atoms. These solvates enable formulations with high concentrations of abscisic acid.

Provided are a treatment apparatus and a treatment method treating a waste cleaning liquid discharged from a process of producing an electrode of a lithium-ion secondary battery, in which a liquid component and a solid component are efficiently separated from each other, and the liquid component can be sufficiently collected and subjected to volume reduction treatment. The treatment apparatus includes: a stirring tank stirring the waste cleaning liquid; a liquid feed line that takes out the waste cleaning liquid from the stirring tank; and a thin film evaporator evaporating a cleaning liquid in the waste cleaning liquid to separate the solid component. Then, in the treatment method, the waste cleaning liquid is stirred in the stirring tank, the waste cleaning liquid is supplied to the thin film evaporator in a state in which the solid component is diffused, and the cleaning liquid in the waste cleaning liquid is evaporated.

The present invention relates to a composition for battery electrodes in which at least one solvent is a composition comprising between 80% and 95% by mass of N-methylpyrrolidone (NMP).